Edgen Stock·Sep 26 2025, 20:47戻る
戻る
Compass Pathways Publishes Positive Phase 2 Data for COMP360 in PTSD
Edgen Stock·Sep 26 2025, 20:47
[1] Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder (https://finance.yahoo.com/news/compass-pathwa ...)[2] Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder | Nasdaq (https://www.nasdaq.com/press-release/2025-09- ...)[3] Bionomics shares soar almost 400% after positive phase IIb results from PTSD treatment (https://vertexaisearch.cloud.google.com/groun ...)